AGAP2 and nonpapillary renal cell carcinoma: Our main finding is that the level of AGAP2-AS1 expression in tumor tissues from the time of the initial surgery correctly predicts 100% of the nonprogressor group and close to 90% of the progressor group of patients with low-risk ccRCC.